Many patients with non-small cell lung cancer (NSCLC) harbor mutations in a gene called EGFR (epidermal growth factor receptor). These individuals are candidates for treatment with targeted therapy using a family of drugs called tyrosine kinase inhibitors (TKIs). However, over time, most EGFR patients develop additional mutations that cause their tumors to become resistant to TKI therapy, and they must be placed on different treatment therapies.
In an effort to better understand mechanisms of EGFR resistance and to identify new drug candidates, ALCF and ALCMI are partnering with the "EGFR Resisters," a group of patients who have come together through the power of social media. This group of individuals now includes over five hundred people around the globe who are working to advance research on EGFR lung cancer by supporting science and projects with the goal to improve outcomes for people with EGFR positive lung cancer. The ultimate objective is changing EGFR positive lung cancer into a manageable chronic disease.
ALCF and the EGFR Resisters will be working together to raise money for and awareness of projects that will support the entire EGFR community.
Please show your support today by making a donation below!
(For any check/cash donations please make sure to indicate which campaign the funds will be credited towards ex: "ALK Positive Fundraiser." Also, for any Wire Transfers, please email email@example.com for more information).
Many employers sponsor matching gift programs and will match charitable contributions made by their employees. To find out if your company has a matching gift policy, enter the company name in the search box below.